We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
MOUNJARO (Eli Lilly Australia Pty Ltd)
Product name
MOUNJARO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
194 (255 working days)
Active ingredients
tirzepatide
Registration type
NCE/NBE
Indication
Type 2 Diabetes Mellitus:
MOUNJARO is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is not tolerated or contraindicated.
- in addition to other medicinal products for the treatment of type 2 diabetes.